The financing news reported by the “Venture Channel”, as well as early-stage entrepreneurial projects in various fields that we are focusing on.

Please check the Venture Capital Daily on August 19. The Venture Capital Daily contains the financing news reported by the “Venture Capital Channel” today, as well as early-stage entrepreneurial projects in various fields that we are paying attention to, enjoy~

Technology

Financing disclosure:

  • First launch | Distribution robot company “Purdue Technology” completed nearly 100 million yuan in B+ round financing, led by Sequoia Capital China Fund

It is learned that the indoor distribution robot company “Purdue Technology” announced on August 19 that it has completed a nearly 100 million yuan B+ round of financing led by Sequoia Capital China Fund. Meituan, Changyingxin Investment, Qichuang Capital, Old shareholders such as Cheng Bohan Fund all followed up. This is the second round of financing completed by Purdue Technology in two months. Purdue has just completed a series B financing of more than 100 million yuan exclusively invested by Meituan on July 1 this year. Click here for details

  • Accelerating the expansion of segmented application areas, “Luoshi Robot” received 100 million yuan in C1 round of financing

It is learned that the light robot company “Luoshi Robot” announced that it has completed a C1 financing of 100 million yuan, invested by Xianghe Capital. This round of financing will be mainly used to accelerate the technological research and development of innovative applications of robots, promote the development of a new generation of intelligent flexible collaborative robot xMate series products, and promote its landing in medical, service, flexible production and other scenarios.

Founded in 2015, Luoshi Robot is a company that continues to pay attention. Its main products include flexible collaborative robots, light industrial robots and high-end intelligent equipment. At present, Luoshi robots have been widely used in vertical fields such as auto parts, 3C electronics, precision machining, and medical treatment. Its business covers more than ten countries in the world including America, Europe, and Asia. Click here for details

    Click here for details

    Knowing materials

    The new crown vaccine is expected to be available at the end of the year. When can ordinary people get the vaccine?

    There are over 21.99 million cases of COVID-19 worldwide. Like several pandemics in history, it seems that only vaccines are the complete solution.

    Behind the rising numbers, the latest news this morning made people breathe a sigh of relief-the chairman of the Sinopharm Group announced that the company’s inactivated COVID-19 vaccine is expected to be launched at the end of December this year, and the price will not be very high. High, less than one thousand yuan for two needles. Although Sinopharm did not disclose more details, it is exciting enough.

    And just two days ago, there was another exciting news from China’s new crown vaccine. The State Intellectual Property Office announced that my country’s first new crown vaccine patent has been approved. It is the “star player” of the new crown vaccine, the adenovirus vector vaccine (Ad5-nCoV vaccine) that has been granted the patent. This is a new crown vaccine jointly declared by the team of Academician Chen Wei of the Academy of Military Medical Research of the Academy of Military Sciences and Cansino Bio.

    After the news was announced, as soon as the market opened on Monday, CanSino Bio’s stock price rose accordingly. Hong Kong stock Cansino Bio-B rose more than 20% in the intraday market, and finally closed up 13.9% to 219.60 Hong Kong dollars. CanSino Bio also rose 4.33% in the A-share market, exceeding the average level of the pharmaceutical sector that day. In the eyes of many stockholders, Cansino Bio has become the “ten times stock king”, because since the beginning of the year, the company’s stock price has risen nearly 280%.

    What does it mean that the new crown vaccine patent is approved? How far are we from getting the new crown vaccine and eliminating the new crown disease? Let us interpret it together…Click here for details

    Pro is its WeChat official account